The alarming rise of medicalisation in India
One of the most fundamental drivers of the obesity epidemic — the expansion of ultra-processed foods —receives comparatively limited attention
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
Air India recently signaled potential pay cuts or de-rostering for cabin crew members with a higher Body Mass Index (BMI), aligning with strict aviation medical guidelines. This announcement coincides with the patent expiry of the anti-obesity drug semaglutide in India, triggering a flood of generic alternatives and sparking a broader debate on the 'medicalisation' of lifestyle and metabolic conditions.
UPSC Perspectives
Health & Social Perspective
India is currently facing a dual burden of malnutrition and an explosion of Non-Communicable Diseases (NCDs) like diabetes, hypertension, and fatty liver disease. A unique epidemiological factor here is the thin-fat phenotype—a genetic predisposition where South Asians accumulate high levels of visceral fat (dangerous fat around internal organs) even when they appear lean and have a normal BMI. This phenomenon challenges Western anthropometric standards and accelerates the onset of metabolic syndromes. The rapid rise in obesity, particularly among children, is driven by an obesogenic environment characterized by the aggressive marketing of ultra-processed foods (UPFs), shrinking urban open spaces, chronic stress, and sedentary work cultures. To combat this systematically, interventions must go beyond individual blame and focus on preventive community health, aligning with the objectives of the .
Governance & Regulatory Perspective
Air India's corporate policy relies on the strict fitness guidelines mandated by the , which categorizes cabin crew with deranged BMIs as 'temporarily unfit'. However, penalizing employees for high BMI or merely prescribing weight-loss drugs reflects the medicalisation of a complex socio-economic issue—treating structural lifestyle problems purely as individual medical or disciplinary defects. Effective governance requires tackling the root causes through robust regulatory frameworks. For instance, the needs to implement stricter front-of-pack labeling (FOPL) to warn consumers about high fat, sugar, and salt (HFSS) content. Addressing public health requires a multi-sectoral approach involving urban planning for better walkability, regulating corporate work hours, and ensuring food safety, rather than relying on punitive corporate policing.
Science & Economic Perspective
The entry of nearly 40 generic versions of the anti-obesity drug semaglutide into the Indian market highlights a critical intersection of biotechnology and intellectual property. Semaglutide is a GLP-1 receptor agonist that mimics a hormone to reduce appetite and insulin resistance. The expiration of its patent allows Indian generic manufacturers to produce affordable versions, showcasing India's strength as the 'pharmacy of the world' under the framework of the . While this improves accessibility to life-saving drugs, economists and health experts warn against the economic burden of lifelong pharmaceutical dependence. Over-reliance on 'magic pill' solutions diverts government and household health expenditure away from sustainable, preventive healthcare and public infrastructure, creating a lucrative market for pharmaceutical giants at the cost of holistic public health.